Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Upper Bollinger Band Walk | Strength | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | -1.25% | |
| Volume Surge | Other | -1.25% | |
| Upper Bollinger Band Walk | Strength | -1.25% | |
| Wide Bands | Range Expansion | -1.25% | |
| Above Upper BB | Strength | -1.25% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 10 hours ago |
| 2x Volume Pace | about 10 hours ago |
| 1.5x Volume Pace | about 10 hours ago |
| 3x Volume Pace | about 10 hours ago |
| Up 5% | about 10 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/06/2024
Eagle Pharmaceuticals, Inc. Description
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Lymphoma Small Cell Lung Cancer Stroke Lung Cancer Toxicology Organic Chemistry Chronic Lymphocytic Leukemia Lymphocytic Leukemia Angioplasty Percutaneous Thrombocytopenia Heparin Treatment Of Chronic Lymphocytic Leukemia Nitrogen Mustards
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 23.52 |
| 52 Week Low | 3.2101 |
| Average Volume | 186,530 |
| 200-Day Moving Average | 7.12 |
| 50-Day Moving Average | 4.25 |
| 20-Day Moving Average | 4.18 |
| 10-Day Moving Average | 4.63 |
| Average True Range | 0.42 |
| RSI (14) | 73.40 |
| ADX | 24.55 |
| +DI | 34.82 |
| -DI | 8.32 |
| Chandelier Exit (Long, 3 ATRs) | 4.78 |
| Chandelier Exit (Short, 3 ATRs) | 4.51 |
| Upper Bollinger Bands | 5.41 |
| Lower Bollinger Band | 2.96 |
| Percent B (%b) | 1.05 |
| BandWidth | 58.67 |
| MACD Line | 0.30 |
| MACD Signal Line | 0.09 |
| MACD Histogram | 0.2127 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.66 | ||||
| Resistance 3 (R3) | 6.70 | 6.36 | 6.47 | ||
| Resistance 2 (R2) | 6.36 | 6.08 | 6.34 | 6.40 | |
| Resistance 1 (R1) | 5.95 | 5.90 | 5.78 | 5.91 | 6.34 |
| Pivot Point | 5.61 | 5.61 | 5.53 | 5.59 | 5.61 |
| Support 1 (S1) | 5.20 | 5.33 | 5.03 | 5.16 | 4.72 |
| Support 2 (S2) | 4.86 | 5.15 | 4.84 | 4.66 | |
| Support 3 (S3) | 4.45 | 4.86 | 4.59 | ||
| Support 4 (S4) | 4.41 |
